Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

ALRN-6924 may prevent hair loss caused by chemotherapy.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Pexidartinib often causes liver issues and fatigue, especially in women.

Oral bicalutamide is safe and effective for female hair loss.

The method accurately and quickly measures silodosin and dutasteride in mixtures.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.